falsefalse

Advanced Endometrial Cancer: Treatment Optimization - Episode 3

Currently Available Treatment Modalities in Endometrial Cancer

, , ,

The panel reviews the current treatment modalities for endometrial cancer and in what circumstances each is considered for a patient.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial Cancer
    EP. 2: Fertility and Other Treatment Considerations for Patients With Advanced Endometrial Cancer
    Now Viewing
    EP. 3: Currently Available Treatment Modalities in Endometrial Cancer
    EP. 4: First-Line Treatments for Patients With Advanced Endometrial Cancer Who Are Unfit for Surgery
    EP. 5: Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer
    EP. 6: Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer
    EP. 7: Treatment Options for Patients with Recurrent Endometrial Cancer
    EP. 8: Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events
    EP. 9: Monitoring Patients on Therapy for Recurrent Endometrial Cancer
    EP. 10: Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer
    EP. 11: Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer
    EP. 12: Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer
    EP. 13: Greatest Unmet Needs for Patients with Endometrial Cancer
    EP. 14: Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

    Related Content:

    Advanced Endometrial Cancer: Treatment OptimizationGynecologic OncologyOncLive Peer Exchange®
    Dr Wagar on the Use of T-DXd in Patients With HER2+ Endometrial Cancer
    Adavosertib Shows Early Antitumor Activity Despite Safety Concerns in Uterine Serous Carcinoma
    Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study
    x